Comprehensive Immune Profiling of Approved Anti-CD20 mAbs Using SeromYx's Fc Effector Function Platform

Shashi Jatiani[1], Amanda Gross[1], Thomas Broge[1], Thomas Linnekin[1], William Graham[1], Peter Hseuh[2], Henry Buda[1], Max Halpern[1], Lev Brown[1] , Amanda Clarke[1], Lenny Moise[1]

[1]SeromYx Systems, Woburn, MA, 01801
[2]ACROBiosystems, Newark, DE, 19711

Introduction

There remains a need for a comprehensive understanding of the mechanisms of action and clinical implications of anti-CD20 mAbs. This study employs SeromYx's comprehensive Fc-effector function platform to profile the Fc-effector functions of approved anti-CD20 mAbs. By utilizing a well-characterized recombinant human full-length CD20 VLP from ACROBiosystems as an antigen, the study aims to compare the biophysical binding and immune cellular effector functions of the first three approved anti-CD20 mAbs.

Additionally, it identifies novel Fc-effector functions that could enhance therapeutic efficacy while also potentially impacting safety risks. Through this detailed analysis, the study strives to contribute valuable insights for the optimization of existing anti-CD20 therapies and better guide the development of next generation mAbs with improved clinical outcomes.

SeromYx System's Advanced Fc Effector Function Platform



Binding of anti-CD20 mAbs to CD20-VLP



Tripartite Fc receptor binding predicts engagement of immune effectors



Confirmation of canonical anti-CD20 Fc effector functions



Unreported anti-CD20 cellular Fc effector functions



Canonical Functions of Clinically Marketed Anti-CD20 mAbs



Previously Unreported Functions of Clinically Marketed Anti-CD20 mAbs

Key Findings

- Biophysical binding assays are predictive of Fc-driven cellular functions
- SeromYx's platform recapitulates known Fc effector functions of approved anti-CD20 mAbs
- Identification of previously unreported effector functions may guide development of improved CD20 mAbs

Contact Information

www.seromyx.com
Shashi.Jatiani@seromyx.com
Abigail.Harris@seromyx.com

SeromYx Systems Poster: Festival of Biologics 2024, Basel.